^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AVC-001

    i
    Other names: AVC-001, GEM3PSCA
    Associations

    News

    Trials
    Company:
    AvenCell Therap, BMS
    Drug class:
    CD3 agonist, PSCA inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (clinicaltrials.gov)
    P1, N=23, Terminated, AvenCell Europe GmbH | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Jun 2023; business decision by sponsor
    Trial termination • Trial primary completion date
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    AVC-001
    over2years
    Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (clinicaltrials.gov)
    P1, N=24, Recruiting, AvenCell Europe GmbH | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    AVC-001